D
espite clear evidence that patients with stage III colorectal cancer (CRC) benefit from postoperative chemotherapy, 1 only about 70% of patients receive it, according to population-based studies. [2] [3] [4] Barriers to the use of guideline-concordant chemotherapy may be health system-or physician-related factors. For example, only 70% of such patients are seen by a medical oncologist postoperatively, 5, 6 and fewer than 75% of those patients receive the recommended chemotherapy. 2 Nonadherence patterns attributed to physicians' clinical judgment have been associated with patient age, comorbidity, and insurance status. [7] [8] [9] Other barriers may be patientrelated such as concerns over economic status, anxiety or other psychosocial stressors, absence of social support, or refusal for unclear reasons. 3, 4, 10, 11 Given the multitude of potential patient-related barriers, 1 approach to improve adherence to chemotherapy recommendations might be to assist patients with establishing realistic expectations. Indeed, previous studies conducted among patients who had breast and prostate cancer have shown that peer support, or exposure to others who have undergone similar diagnoses and treatment, can improve patient acceptance of and coping with cancer-or cancer treatment-related distress. 12 Peer support interventions for such patients have demonstrated improved satisfaction with medical care, enhanced coping skills, and comfort with proposed treatment plans. [13] [14] [15] [16] [17] [18] However, compared with breast and prostate cancer, patients with CRC experience a host of clinically challenging and socially stigmatizing issues, and they lack the sophisticated patient advocacy that has evolved among the other cancer communities. [19] [20] [21] Furthermore, the specific effect of peer support on CRC patients' attitudes toward and adherence to recommended chemotherapy is entirely unknown. We hypothesized that patients who had exposure to peer support would be more adherent to chemotherapy recommendations and investigated the specific causal effects of peer support exposure on patients' attitudes toward postoperative chemotherapy.
METHODS
Our primary analysis focused on the relationship between exposure to peer support, patient characteristics, and receipt of chemotherapy. We performed a secondary analysis among those exposed to peer support to understand how it affected attitudes toward and coping with chemotherapy.
Study Population
We identified all patients with stage III colon or rectal cancer diagnosed between August 2011 and March 2013 through the Surveillance, Epidemiology and End Results cancer database of Metropolitan Detroit, Michigan (Oakwood, DeKalb, and Wayne Counties) and the State of Georgia. Patients greater than 21 years old at the time of diagnosis were eligible and recruited within 3 to 12 months after CRC resection. Exclusion criteria included stage IV diagnosis, a change in diagnosis based on final pathology results, residence outside the catchment area, or death before survey deployment.
Data Collection
Patients were identified based on pathology reports, and their corresponding physicians were notified about the upcoming survey and invited to opt out. Patients of the physicians who did not opt out were then contacted by mail and invited to participate in the survey. A modified Dillman approach was used for recruitment as previously described. 22 Once the surveys were returned, extensive data checks for logic, errors, and/or omissions were performed, and patients were contacted to obtain any missing information.
This study protocol was approved by the institutional review boards of the University of Michigan, Wayne State University, Emory University, the State of Michigan, and the State of Georgia Department of Public Health. All surveys included an information sheet that explained the study purpose, risks and benefits of participation, as well as assurances of maintaining patient confidentiality.
Measures
The primary outcome of the study was receipt of adjuvant chemotherapy, based on self-reported data. In comparison with claims data, patient self-report is 98% accurate with respect to use of chemotherapy. 23, 24 The primary exposure was peer support, which the survey (see Appendix 1, http:// links.lww.com/DCR/A651) defined as "support received from another person with colorectal cancer." To confirm reliability in response to receipt of peer support, a second question assessing the same underlying construct (peer support) was asked. Only those with consistent responses of "no peer support" for both questions were defined as such, and all responses were consistent between the 2 questions.
Respondents were asked how much support they received from others with CRC using a 5-point Likert response scale, ranging from "none" to "a lot." Responses were then dichotomized for analytic purposes to "received" ("a little" to "a lot") or "not received" ("none"). Patients were asked to assess the amount or adequacy of support by asking if the amount of peer support had been "too little," "just right," or "too much." This was again dichotomized to "adequate" ("just right" or "too much") or "inadequate" ("too little"). Patients were then asked to evaluate how peer support affected their attitudes toward the use of chemotherapy. Favorable or positive responses included "it helped me know what to expect," "it helped me cope with challenges and side effects of treatment," "it helped me make treatment decisions," and "it helped me emotionally." Adverse or negative responses included "it made me doubt my treatment decisions," "it made me feel anxious about treatment," and "it made me wonder why I didn't get the same treatments they had."
These causal responses were derived from a pilot focus group study followed by testing through cognitive interviews that occurred after survey construction and before deployment. Additional covariates in the survey included self-reported demographics including age at diagnosis, sex, race, marital status, highest level of education, and income.
Statistical Analysis
We identified associations between exposure to peer support, patients' sociodemographic characteristics, and chemotherapy adherence by using χ 2 tests and multivariable logistic regression. In a secondary analysis that included only patients who reported exposure to peer support, we performed multivariable logistic regressions, adjusting for the significant variables found on bivariate analysis, to examine the association between exposure-related attitudes and chemotherapy adherence. All statistical tests were 2-sided and p values of <0.05 were considered statistically significant. All analyses were conducted by using SAS version 9.4 software (SAS Institute, Inc., Cary, NC). Income data were missing for 20% of respondents and were imputed using multiple imputation techniques. All other covariates had less than 1% missing values. Weights were developed to account for patient response rates and included in all multivariate analyses.
RESULTS

Study Sample and Response Rate
Of the 1901 eligible patients identified in the Surveillance, Epidemiology and End Results registries of Georgia and Metropolitan Detroit, 1301 completed the survey for a 68% response rate. Six hundred patients (32%) could not be located or did not complete or return the survey. One hundred forty-six (11%) respondents did not complete the questions regarding peer support exposure and were therefore excluded from analysis. This yielded a total of 1155 patients for analysis (Fig. 1) .
Respondent Characteristics and Peer Support
Peer support exposure was reported by 553 (48%) of the respondents; 602 respondents (52%) reported the absence of peer support following diagnosis. Patient characteristics that were statistically significantly associated with peer support included age, marital status, and annual income. Sex, race, and education levels were not associated with exposure to peer support (Table 1) .
These relationships remained robust in multivariable logistic regression. Patients were more likely to receive peer support if they were younger (<50 years old versus ≥75 years old: OR, 2.86; 95% CI, 1.85-4.35), if they were married (OR, 1.47; 95% CI, 1.09-1.98), or if they had a higher income (≥$90,000 versus <$20,000: OR, 1.84; 95% CI, 1.10-3.08). There were no statistically significant associations based on race, sex, or education (Table 2) .
Peer Support and Chemotherapy Adherence
Patients who reported any peer support overall were more likely to receive adjuvant chemotherapy than those who reported no peer support (OR, 2.94; 95% CI, 1.89-4.55).
Comparisons of the patient-reported adequacy of the peer support with the lack of peer support demonstrated that there was increased receipt of chemotherapy among those with "inadequate peer support," but this was not statistically significant after adjustments (OR, 1.72; 95% CI, 0.79-3.75). "Adequate peer support," however, had a statistically significant correlation with increased chemotherapy receipt (OR, 2.91; 95% CI, 1.47-5.75) ( Table 3) . 
Effects of Peer Support on Attitudes
Toward Chemotherapy A secondary analysis was performed to characterize the specific attitudinal effects of peer support and the association with chemotherapy adherence. Compared with their counterparts, male respondents (p = 0.006), black respondents (p = 0.015), and those who reported an annual income between $20,000 and $49,999 (p = 0.001) and had "some college education" (p = 0.005) were more likely to indicate that peer support "helped me make treatment decisions." Black respondents (p = 0.006) and those who reported an annual income between $20,000 and $49,999 (p = 0.035) were more likely to indicate that peer support "helped me emotionally." Black respondents (p = 0.049) were also more likely to indicate that peer support "helped me know what to expect" with regard to postoperative chemotherapy. Finally, patients who reported an annual income between $20,000 and $49,999 (p = 0.031) were more likely to indicate that peer support "made me wonder why I didn't get the same treatment they had" than those with higher income levels. Regarding the effects of peer support on attitudes, for the most part, respondents who indicated that peer support was helpful (eg, "helped me know what to expect" or "helped me cope with the challenges and side effects of treatment") were more likely to adhere to chemotherapy recommendations than those who did not report these changes (OR, 1.70; 95% CI, 1.02-2.84 and OR, 5.92; 95% CI, 3.30-10.53) ( Table 4) . However, those who reported that peer support "helped me make treatment decisions" (n = 184) were less likely to receive adjuvant chemotherapy than those who did not report this effect (OR, 0.47; 95% CI, 0.26-0.82). Among those who did not receive chemotherapy, 56% reported concern about the associated side effects or complications as reasons for nonadherence.
Respondents that indicated adverse effects of peer support exposure ("made me scared or anxious about treatment," "made me doubt my treatment decisions," and "made me wonder why I didn't get the same treatments they had") were not significantly different from their counterparts in chemotherapy adherence (p = 0.12, p = 0.82, and p = 0.47).
DISCUSSION
In this population-based study of patients with stage III CRC, respondents who reported any exposure to peers with CRC were significantly more likely to also report receipt of recommended adjuvant chemotherapy. Additionally, we identified a statistically significant association between the favorable effects of peer support on patients' attitudes and adherence to recommended therapy. Given that the use of adjuvant chemotherapy for stage III CRC can reduce mortality by up to 33% and recurrence by up to 41%, 25 identifying opportunities, such as peer support programs, for improving adherence is critical to improving CRC outcomes.
Respondents reported that exposure to peer support had a largely favorable effect on their attitudes toward treatment options which may have extended to behaviors. For example, among the 75% of respondents who indicated that it "helped them know what to expect" and the 71% who reported that it "helped them deal with the challenges and side effects of treatment," we identified a significant increase in chemotherapy adherence. Our findings are consistent with the only other study, to our knowledge, that investigated the utility of peer support available to CRC patients encompassing 121 patients in Australia. The authors found the key features that patients found useful included information about treatments for CRC, treatment side effects, managing symptoms, and how to be involved in treatment decision making. 26 Regarding the negative effects of peer support, we were surprised to find that patients who described peer support as "helping me make treatment decisions" were actually less likely to adhere to chemotherapy recommendations. We note that the majority of patients who gave this response also reported receiving "inadequate peer support," which was not significantly associated with chemotherapy adherence. These patients were also more likely to report fear of side effects as a reason for nonadherence. Although there is little to no published literature detailing negative consequences of peer support among patients with cancer, reinforcement of negative behaviors and diminished feelings of self-efficacy have been proposed as a possible mechanism. 12 The potential for ineffective or adverse peer support therefore highlight the critical need for structure and training among those providing it in a formal setting.
Our study finding that CRC patients who were younger (<50 years) had a higher income (≥$90,000), or were married, were more likely to receive support from peers with CRC are consistent with prior studies of patients with other types of cancer. 2, 3, 13 Taken together, these data may help to define contrasting patient groups that are less likely to receive spontaneous peer support and therefore could derive particular benefit from a structured peer support program. The association between older age and decreased receipt of CRC chemotherapy in the absence of clinical contraindications is well established. 2 Whether this is a result of clinician bias or patient decision making is less clear; for example, older patients may refuse chemotherapy because of concern for worsening quality of life. 27 Thus, this population may especially benefit from speaking with others who have already been treated with chemotherapy.
We also found that patients with a lower income (<$20,000) were less likely to receive peer support than their more affluent counterparts (≥$90,000). Previous work from our group revealed that patients with lower incomes reported high levels of worry about the financial burden associated with chemotherapy. 22 Such a vulnerable subset of patients may be worth targeting by facilitated peer support programs to mitigate financial concerns that function as a deterrent to chemotherapy adherence. Although education and income were correlated, we did not identify a significant relationship between education and peer support, nor did we find mediator or moderator variables to explain this phenomenon. It is possible that the resources afforded to those with the highest level of income allowed for additional opportunities to seek peer support.
We also note that respondents who were married or partnered were more likely to report exposure to peer sup- 14,28
Our study was subject to several limitations inherent to survey research that should be noted. Although the survey response rate of 68% was high, it is possible that nonrespondents differed from respondents in ways that could affect generalizability. In addition, respondents may have been subject to recall bias. However, this limitation was mitigated by strict adherence to distribution of surveys within 4 months of surgery (when chemotherapy should have been initiated) and acceptance of completed surveys only up to 1 year after surgery. Any survey returned after this date was not included to limit the possibility of recall bias. Finally, although we explored the self-reported effects of peer support on patient attitudes toward chemotherapy, further evaluation is warranted to clarify whether a causal rather than simply an associative relationship exists between peer support and chemotherapy adherence. Disruptions to this causal pathway could include respondents being exposed to peer support once they had already initiated chemotherapy because they would have increased opportunities for meeting other patients with CRC during their treatment sessions. Alternatively, patients could have sought out peer support when having difficulty coping with the side effects of the treatment. That said, we believe the current survey results provide sufficient evidence to warrant further study of such a relationship. As well, we would recommend exploration of the perceived differences in the quality of peer support received, a potential temporal relationship between peer support and chemotherapy initiation, and the relative impact of informal versus structured peer support programs. Such research could inform the development of a mechanistic model on which to base structured peer support opportunities for CRC patients.
CONCLUSION
We found that exposure to peer support was associated with receipt of chemotherapy among patients with stage III CRC, and that this association may be based on improved patient attitudes and coping skills related to CRC treatment. We also identified patients with the greatest unmet need for support, who may be most likely to benefit from a targeted intervention. As the first physicians to treat CRC patients, surgeons play a leading role in their multidisciplinary care and often initiate discussions of adjuvant chemotherapy. Moreover, surgeons engender extremely high levels of trust among patients and, therefore, may be the ideal team members to introduce a potential future peer support intervention to improve patient expectations, coping, and adherence to treatment recommendations. 29 
